Company profile
REPLIGEN CORP
NASDAQ:RGENBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Uridine triacetate | phase1 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00812058 | phase2 | completed | 2008-11-01 | 2010-12-01 | Repligen Corporation | A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression |
| NCT00322764 | phase2 | completed | 2006-03-01 | — | Repligen Corporation | Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression |
| NCT00060515 | phase1 | terminated | — | — | Repligen Corporation | RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease |
| NCT00660335 | phase3 | completed | 2008-03-01 | 2009-10-01 | Repligen Corporation | Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas |
| NCT00036244 | phase3 | completed | 2002-04-01 | — | Repligen Corporation | Synthetic Human Secretin in Children With Autism |
FDA applications (0)
No records yet.